Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Oramed Pharmaceuticals  / Equity Bottom-Up

<ul><li> ORMP is leveraging its strong balance sheet - ~$142m in cash, equivalents, ST investments & deposits, no LT debt - to optimize its cash position.</li><li>The company is augmenting its cash position with repayments / interest from collateralized loans issued to Scilex & to a domestic real estate project.</li><li>Management expects its resources are sufficient to maintain planned activities for roughly at least the next year as clinical activities pick-up and as it maintains strategic share repurchases under its 2024 share buyback plan.</li></ul>

 ORMP is leveraging its strong balance sheet - ~$142m in cash, equivalents, ST investments & deposits, no LT debt - to optimize its cash position.The company is augmenting its cash position with repayments / interest from collateralized loans issued to Scilex & to a domestic real estate project.Management expects its resources are sufficient to maintain planned activities for roughly at least the next year as clinical activities pick-up and as it maintains strategic share repurchases under its 2024 share buyback plan.

ORMP: Preparations for New Phase 3 Trial Advance